MediciNova Inc (MNOV.OQ)
MNOV.OQ on NASDAQ Stock Exchange Global Market
8.53USD
20 Jul 2018
8.53USD
20 Jul 2018
Change (% chg)
$-0.40 (-4.48%)
$-0.40 (-4.48%)
Prev Close
$8.93
$8.93
Open
$8.90
$8.90
Day's High
$8.95
$8.95
Day's Low
$8.51
$8.51
Volume
46,780
46,780
Avg. Vol
56,464
56,464
52-wk High
$14.50
$14.50
52-wk Low
$4.40
$4.40
About
Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029... (more)
Overall
| Beta: | 0.25 |
| Market Cap(Mil.): | ¥24,203.37 |
| Shares Outstanding(Mil.): | 35.35 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
BRIEF-MediciNova to collaborate with UCLA researchers in grant-funded clinical trial of MN-166 (ibudilast) in alcohol use disorder and withdrawal
* Says it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA)
BRIEF-MediciNova Announces Proposed Underwritten Public Offering
* MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
BRIEF-Medicinova Announces Phase 2B Trial results in MN-166 (Ibudilast)
* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) DEMONSTRATED A 26 PCT REDUCTION IN CONFIRMED DISABILITY PROGRESSION IN THE SPRINT-MS PHASE 2B TRIAL IN PROGRESSIVE MS: POTENTIAL BEST-IN-DISEASE DRUG Source text for Eikon: Further company coverage:
Estimates